Preliminary analysis of chronic gastrointestinal toxicity in gynecology patients treated with intensity-modulated whole pelvic radiation therapy.

PURPOSE To provide a preliminary analysis of chronic gastrointestinal (GI) toxicity in gynecology patients treated with intensity-modulated whole pelvic radiation therapy (IM-WPRT). METHODS AND MATERIALS Between February 2000 and August 2001, 36 gynecology patients received IM-WPRT. All patients underwent a contrast-enhanced computed tomography scan, and a clinical target volume (CTV) was contoured consisting of the upper vagina, parametria, uterus (if present), and presacral and pelvic lymph node regions. The CTV was expanded by 1 cm to create a planning target volume (PTV). Seven or 9-field IM-WPRT plans were generated. IM-WPRT plans were highly conformal, providing excellent coverage of the PTV and considerable sparing of normal tissues, including the small bowel and rectum. Chronic GI toxicity was scored: 0 (no symptoms), 1 (mild symptoms, no medications required), 2 (moderate symptoms, medications required), and 3 (severe symptoms, hospitalization, surgery required). Chronic GI toxicity in 30 gynecology patients treated with conventional WPRT patients before the implementation of IM-WPRT was also evaluated. Median follow-up in the IM-WPRT and WPRT groups were 19.6 and 30.2 months, respectively. RESULTS The IM-WPRT and WPRT groups were well balanced in terms of most patient and treatment factors, including age, site, stage, chemotherapy, WPRT dose, and brachytherapy, except for a higher frequency of surgery (75 vs. 54%, p = 0.02) in the IM-WPRT group. Overall, IM-WPRT patients had a lower rate of chronic GI toxicity (11.1 vs. 50.0%, p = 0.001) than WPRT patients. The percentage of IM-WPRT patients with Grade 1, 2, and 3 toxicity were 8.3%, 2.8%, and 0%, respectively. Corresponding percentages in the WPRT group were 30.0%, 16.7%, and 3.3%, respectively. The only other factor correlated with chronic GI toxicity was age (p = 0.02). On multivariate (logistic regression) analysis controlling for age and other clinical factors, IM-WPRT retained its statistical significance (p = 0.01; odds ratio 0.16; 95% confidence interval 0.04, 0.67) CONCLUSIONS Our results suggest that IM-WPRT is associated with less chronic GI toxicity than conventional WPRT in patients with gynecologic malignancies. However, longer follow-up and more patients are clearly needed to ascertain whether the benefits of IM-WPRT treatment seen here translate into true long-term reductions in chronic GI toxicity.

[1]  D. Schultz,et al.  Impact of improved irradiation technique, age, and lymph node sampling on the severe complication rate of surgically staged endometrial cancer patients: a multivariate analysis. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  C. Dalrymple,et al.  Adjuvant high-dose rate brachytherapy with or without external beam radiotherapy post-hysterectomy for endometrial cancer. , 1999, International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.

[3]  Linda Hong,et al.  IMRT of large fields: whole-abdomen irradiation. , 2001, International journal of radiation oncology, biology, physics.

[4]  P. Koper,et al.  Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial , 2000, The Lancet.

[5]  W. D'Souza,et al.  Intensity modulated radiation therapy (IMRT) for post-hysterectomy pelvic radiation: selection of patients and planning target volume (PTV) , 2002 .

[6]  J. Roeske,et al.  Intensity-modulated whole pelvic radiation therapy in patients with gynecologic malignancies. , 2000, International journal of radiation oncology, biology, physics.

[7]  J. Jassem,et al.  Late complications after postoperative radiotherapy in endometrial cancer: analysis of 317 consecutive cases with application of linear-quadratic model. , 1998, International journal of radiation oncology, biology, physics.

[8]  J. Purdy,et al.  Radiation therapy alone in the treatment of carcinoma of the uterine cervix. II. Analysis of complications , 1984, Cancer.

[9]  F. Fang,et al.  The correlation of acute toxicity and late rectal injury in radiotherapy for cervical carcinoma: evidence suggestive of consequential late effect (CQLE). , 1998, International journal of radiation oncology, biology, physics.

[10]  John C Roeske,et al.  Impact of intensity-modulated radiotherapy on acute hematologic toxicity in women with gynecologic malignancies. , 2002, International journal of radiation oncology, biology, physics.

[11]  R. Mohan,et al.  Clinical application of intensity-modulated radiotherapy for locally advanced cervical cancer. , 2002, Seminars in radiation oncology.

[12]  P. Grigsby,et al.  Radiotherapy alone for medically inoperable carcinoma of the cervix: stage IA and carcinoma in situ. , 1991, International journal of radiation oncology, biology, physics.

[13]  J. Roeske,et al.  Late rectal sequelae following definitive radiation therapy for carcinoma of the uterine cervix: a dosimetric analysis. , 1997, International journal of radiation oncology, biology, physics.

[14]  J. Roeske,et al.  Initial clinical experience with intensity-modulated whole-pelvis radiation therapy in women with gynecologic malignancies. , 2001, Gynecologic oncology.

[15]  John C Roeske,et al.  Intensity-modulated radiotherapy as a means of reducing dose to bone marrow in gynecologic patients receiving whole pelvic radiotherapy. , 2001, International journal of radiation oncology, biology, physics.

[16]  B N Bundy,et al.  Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma. , 1999, The New England journal of medicine.

[17]  J. Davelaar,et al.  Vitamin B12 malabsorption after irradiation for gynaecological tumours. , 1993, Anticancer research.

[18]  A. Mundt,et al.  Preoperative intracavitary brachytherapy in early-stage cervical carcinoma. , 1999, American journal of clinical oncology.

[19]  D Low,et al.  Intensity-modulated radiation therapy (IMRT) reduces small bowel, rectum, and bladder doses in patients with cervical cancer receiving pelvic and para-aortic irradiation. , 2001, International journal of radiation oncology, biology, physics.

[20]  Icru.  Prescribing, recording, and reporting photon beam therapy , 1993 .

[21]  J. Kearsley,et al.  The relationship between early and late gastrointestinal complications of radiation therapy for carcinoma of the cervix. , 1983, International journal of radiation oncology, biology, physics.

[22]  B N Bundy,et al.  A randomized trial of pelvic radiation therapy versus no further therapy in selected patients with stage IB carcinoma of the cervix after radical hysterectomy and pelvic lymphadenectomy: A Gynecologic Oncology Group Study. , 1999, Gynecologic oncology.

[23]  J. Roeske,et al.  Intensity-modulated radiation therapy in gynecologic malignancies. , 2002, Current treatment options in oncology.

[24]  J. Roeske,et al.  Dose-volume histogram analysis of acute gastrointestinal toxicity for gynecologic patients receiving intensity-modulated whole pelvic radiotherapy , 2001 .

[25]  P. Koper,et al.  The morbidity of treatment for patients with Stage I endometrial cancer: results from a randomized trial. , 2001, International journal of radiation oncology, biology, physics.

[26]  J. Roeske,et al.  Clinical experience with Intensity-Modulated Whole Pelvic Radiation Therapy (IM-WPRT) in patients with gynecologic malignancies , 2001 .

[27]  B. Emami,et al.  Comparison of IMRT with 3-D CRT for gynecologic malignancies , 2001 .

[28]  John C Roeske,et al.  Intensity-modulated whole pelvic radiotherapy in women with gynecologic malignancies. , 2002, International journal of radiation oncology, biology, physics.

[29]  B N Bundy,et al.  Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. , 1999, The New England journal of medicine.